Bluewater Bio Secures Sale of its HYBACS Process in South Africa
Project is for first phase extension to Botleng Sewage Treatment Plant
Bluewater Bio, Ltd., announced that it has secured the first sales of its HYBACS process in South Africa.
The project, secured via Bluewater Bio’s licensing agreement with Headstream Water Holdings, is for the first phase extension to the Botleng Sewage Treatment Plant. Bluewater Bio’s HYBACS (Hybrid Bacillus Activated Sludge) process will be deployed and two of its SMART (Shaft Mounted Advanced Reactor Technology) units, which drive the process, will be installed. The plant extension has been designed to treat 7,000 cu meters per day, with the first phase extension being 3,500 cu meters per day. The second phase to complete the extension is expected to follow once the municipality has secured the required budget. The plant will be owned and operated by the Victor Khanye Local Municipality.
The Botleng Sewage Treatment Plant services the town of Delmas in the Mpumulanga Province. Delmas lies 60 km east of Johannesburg and has a population of approximately 92,000. Botleng is one of two sewage treatment plants (STPs) in the town, the other being the Delmas STP. These sewage treatment facilities have to produce effluents that comply with the specifications of the relevant authorities, including nutrient removal. The local municipality sees the capacity expansion at these two STPs as a top priority given the continued growth of the town and the municipality’s commitment to providing sanitation services to the community.
“We are delighted to have secured the first sales of our HYBACS technology in South Africa following our exclusive licensing agreement with Headstream Water Holdings last year,” said Daniel Ishag, CEO of Bluewater Bio. “This contract will give Bluewater Bio its first full scale reference site in Sub-Saharan Africa, providing us with a strong platform for the commercial rollout of HYBACS throughout the region.”